Exact Mass: 674.3991316
Exact Mass Matches: 674.3991316
Found 207 metabolites which its exact mass value is equals to given mass value 674.3991316,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
I07-0299
Cimicifugoside is a triterpenoid. CID 441913 is a natural product found in Actaea racemosa with data available.
Cimicifugoside
PA(12:0/20:3(8Z,11Z,14Z)-2OH(5,6))
PA(12:0/20:3(8Z,11Z,14Z)-2OH(5,6)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(12:0/20:3(8Z,11Z,14Z)-2OH(5,6)), in particular, consists of one chain of one dodecanoyl at the C-1 position and one chain of 5,6-dihydroxyeicosatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(20:3(8Z,11Z,14Z)-2OH(5,6)/12:0)
PA(20:3(8Z,11Z,14Z)-2OH(5,6)/12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(8Z,11Z,14Z)-2OH(5,6)/12:0), in particular, consists of one chain of one 5,6-dihydroxyeicosatrienoyl at the C-1 position and one chain of dodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(i-12:0/20:3(8Z,11Z,14Z)-2OH(5,6))
PA(i-12:0/20:3(8Z,11Z,14Z)-2OH(5,6)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-12:0/20:3(8Z,11Z,14Z)-2OH(5,6)), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of 5,6-dihydroxyeicosatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(20:3(8Z,11Z,14Z)-2OH(5,6)/i-12:0)
PA(20:3(8Z,11Z,14Z)-2OH(5,6)/i-12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(8Z,11Z,14Z)-2OH(5,6)/i-12:0), in particular, consists of one chain of one 5,6-dihydroxyeicosatrienoyl at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
21,24-epoxy-3alpha,7alpha,21,23-tetraacetoxy-25-hydroxy-4alpha,4beta,8beta-trimethyl-14,18-cyclo-5alpha,13alpha,14alpha,17alpha-cholestane
3,21,22,28-Tetra-Ac -(3beta,16alpha,21beta,22alpha)-12-Oleanene-3,16,21,22,23,28-hexol|3,21,22,28-Tetra-Ac-12-Oleanene-3,16,21,22,23,28-hexol
25(S)-22-methoxy-1beta,3beta,4beta,5beta,26-pentahydroxy-furost-26-yl O-beta-D-glucopyranoside
7-hydroxy-8,14-diisobutyl-2,2,4,4,10,10,12,12-octamethyl-6-(3-methylbutyryl)-4,8,12,14-tetrahydro-5,13-dioxapentaphene-1,3,9,11-tetraone|rhodomyrtosone C
(4R,9beta,16alpha,24S)-25-methoxy-9,10,14-trimethyl-1,11,22-trioxo-16,24-epoxy-4,9-cyclo-9,10-secocholesta-2,5-dien-2-yl beta-D-glucopyranoside|16alpha,24alpha-epoxy-2-hydroxy-25-methoxy-3,11,22-trioxo-cucurbita-1,5-diene 2-O-beta-D-glucopyranoside|colocynthin C
3-acetyl-2-(3-hydroxy-3-methyl)glutarylanhydrocrustulinol
3,23-O-hydroxyethylidene-3beta,23-dihydroxyurs-12,19(20)-dien-28-oic acid 28-beta-D-glucopyranosyl ester|oblonganoside A
(6Z,9Z,12Z,15Z)-octadeca-6-9-12-15-tetraenoic acid (2R)-3-[(6-O-alpha-galactopyranosyl-beta-D-galactopyranosyl)oxy]-2-hydroxypropyl ester|sarcoglycoside A
2beta,23-Dihydroxy-3-O-(4-deoxy-beta-L-threo-hex-4-enopyranosiduronic acid)-olean-12-en-28-oic acid
Lys Arg Trp Trp
Lys Trp Arg Trp
Lys Trp Trp Arg
Arg Lys Trp Trp
Arg Trp Lys Trp
Arg Trp Trp Lys
Trp Lys Arg Trp
Trp Lys Trp Arg
Trp Arg Lys Trp
Trp Arg Trp Lys
Trp Trp Lys Arg
Trp Trp Arg Lys
DGMG 18:4
19-Hydroxyfucoxanthin
H-Ser-Ile-Gly-Ser-Leu-Ala-Lys-OH trifluoroacetate salt
Maralixibat
C78276 - Agent Affecting Digestive System or Metabolism > C177170 - Ileal Bile Acid Transport Inhibitor
Oblonganoside A
A triterpenoid saponin thatr is the beta-D-glucopyranosyl ester of 3,23-O-hydroxyethylidene-3beta,23-dihydroxyurs-12,19(20)-dien-28-oic acid. Isolated from Ilex oblonga, it exhibits activity against TMV.
Trichodepsipeptide B
C35H54N4O9 (674.3890594000001)
A natural product found in Trichothecium speciesMSX 51320.
Veraguamide H, (rel)-
A natural product found in Oscillatoria margaritifera PAC-17-FEB-10-2.
N-[(3R,9R,10R)-12-[(2R)-1-hydroxypropan-2-yl]-9-[[[(4-methoxyanilino)-oxomethyl]-methylamino]methyl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-2-phenylacetamide
4-(dimethylamino)-N-[(3R,9R,10R)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-[[methyl-(4-methylphenyl)sulfonylamino]methyl]-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]butanamide
N-Acetylleucylleucylleucylleucyltyrosinamide
C35H58N6O7 (674.4366758000001)
2-[[(2R)-2-[(E)-5,8-dioxooct-6-enoyl]oxy-3-[(Z)-octadec-9-enoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
[(4E,8E,12E)-3-hydroxy-2-[[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]amino]pentadeca-4,8,12-trienyl] 2-(trimethylazaniumyl)ethyl phosphate
[1-[(2-heptanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (10Z,13Z,16Z)-docosa-10,13,16-trienoate
[1-hydroxy-3-[hydroxy-(3-hydroxy-2-nonanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (11Z,14Z,17Z)-icosa-11,14,17-trienoate
[1-hydroxy-3-[hydroxy-(3-hydroxy-2-undecanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate
[1-hydroxy-3-[hydroxy-[3-hydroxy-2-[(Z)-tridec-9-enoyl]oxypropoxy]phosphoryl]oxypropan-2-yl] (9Z,12Z)-hexadeca-9,12-dienoate
[1-hydroxy-3-[hydroxy-(3-hydroxy-2-tridecanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-nonanoyloxypropan-2-yl] (11Z,14Z,17Z)-icosa-11,14,17-trienoate
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-heptanoyloxypropan-2-yl] (10Z,13Z,16Z)-docosa-10,13,16-trienoate
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tridec-9-enoyl]oxypropan-2-yl] (9Z,12Z)-hexadeca-9,12-dienoate
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-undecanoyloxypropan-2-yl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate
[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-tridecanoyloxypropan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate
[(2S)-3-[[(2R)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-undecanoyloxypropyl] (6E,9E,12E)-octadeca-6,9,12-trienoate
[2-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxy-3-phosphonooxypropyl] (4E,7E,10E,13E,16E)-nonadeca-4,7,10,13,16-pentaenoate
[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(E)-tridec-8-enoyl]oxypropan-2-yl] (4E,7E)-hexadeca-4,7-dienoate
[2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-3-phosphonooxypropyl] (7E,10E,13E,16E)-nonadeca-7,10,13,16-tetraenoate
[(2S)-3-[[(2R)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-undecanoyloxypropyl] (9E,12E,15E)-octadeca-9,12,15-trienoate
[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-undecanoyloxypropan-2-yl] (9E,12E,15E)-octadeca-9,12,15-trienoate
[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-tridecanoyloxypropan-2-yl] (9E,11E,13E)-hexadeca-9,11,13-trienoate
[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-undecanoyloxypropan-2-yl] (6E,9E,12E)-octadeca-6,9,12-trienoate
[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-phosphonooxypropyl] (10E,13E,16E)-nonadeca-10,13,16-trienoate
N-Acetyl-leu-leu-leu-leu-tyr-amide
C35H58N6O7 (674.4366758000001)
phosphatidylserine 28:2(1-)
A 3-sn-phosphatidyl-L-serine(1-) in which the acyl groups at C-1 and C-2 contain 28 carbons in total and 2 double bonds.
(2r,3s,4s,5r,6r)-4-{[(2s,3r,4s,5s)-5-[(1r)-1,2-dimethoxyethyl]-3,4-dimethoxyoxolan-2-yl]oxy}-3,5-dimethoxy-2-(methoxymethyl)-6-{[(2s,3r,4s,5r)-1,2,4,5,6-pentamethoxyhexan-3-yl]oxy}oxane
(3s,6s,9s,12s,15s,18s)-15-benzyl-8,11,17-trihydroxy-6-(hydroxymethyl)-3,9-diisopropyl-13-methyl-12,18-bis(2-methylpropyl)-1,4-dioxa-7,10,13,16-tetraazacyclooctadeca-7,10,16-triene-2,5,14-trione
C35H54N4O9 (674.3890594000001)
(1r,2r,3ar,5as,7s,9as,11as)-1-[(3r,5s)-5-[(2r,3s)-2-isopropyl-3-methyloxiran-2-yl]-2-oxooxolan-3-yl]-9a,11a-dimethyl-7-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,3ah,5h,5ah,6h,7h,8h,9h,11h-cyclopenta[a]phenanthren-2-yl acetate
3,4-dimethoxy-6-(methoxymethyl)-2-[(1,2,4,5,6-pentamethoxyhexan-3-yl)oxy]-5-{[3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy}oxane
4',5,6',12',17',17'-hexamethyl-4-oxo-18'-[(3,4,5-trihydroxyoxan-2-yl)oxy]-3,6,9'-trioxaspiro[bicyclo[3.1.0]hexane-2,8'-hexacyclo[11.9.0.0¹,²¹.0⁴,¹².0⁵,¹⁰.0¹⁶,²¹]docosan]-3'-yl acetate
(2r,3r,4s,5s,6r)-3,4-dimethoxy-6-(methoxymethyl)-2-{[(2s,3r,4s,5r)-1,2,4,5,6-pentamethoxyhexan-3-yl]oxy}-5-{[(2r,3r,4s,5s,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy}oxane
4-hydroxy-4',5,6',12',17',17'-hexamethyl-18'-[(3,4,5-trihydroxyoxan-2-yl)oxy]-3,6,9'-trioxaspiro[bicyclo[3.1.0]hexane-2,8'-hexacyclo[11.9.0.0¹,²¹.0⁴,¹².0⁵,¹⁰.0¹⁶,²¹]docosan]-13'-en-3'-yl acetate
(2e,4s,5s,6e,8e)-10-[(2r,5s,7r,8s)-2-[(1s,2e,4e)-5-carboxy-1-[(3-carboxypropanoyl)oxy]-4-methylpenta-2,4-dien-1-yl]-8-methyl-2-pentyl-1,6-dioxaspiro[4.5]decan-7-yl]-5-hydroxy-4,8-dimethyldeca-2,6,8-trienoic acid
6-(2-methoxypropan-2-yl)-2,9,11,14,19,19-hexamethyl-17-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-oxapentacyclo[12.8.0.0²,¹¹.0⁴,¹⁰.0¹⁵,²⁰]docosa-16,20-diene-8,13,18-trione
3-{[2,4-dihydroxy-6-(15-methyl-14-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}heptadeca-3,5-dien-1-yl)phenyl]methyl}-4-hydroxy-6-methylpyran-2-one
13-hydroxy-2,2,4,4,8,8,10,10-octamethyl-12-(3-methylbutanoyl)-6,14-bis(2-methylpropyl)-6,14-dihydro-5,11-dioxapentaphene-1,3,7,9-tetrone
(1s,3r,6s,8r,12s,13r,15r,16r,17r)-15-[(2r)-4-[(2r)-3,3-dimethyloxiran-2-yl]-4-oxobutan-2-yl]-13-hydroxy-7,7,12,16-tetramethyl-14-oxo-6-{[(2s,3r,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxy}pentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadec-10-en-17-yl acetate
3-hydroxy-4-(18-{4-hydroxy-2,2,6-trimethyl-7-oxabicyclo[4.1.0]heptan-1-yl}-3-(hydroxymethyl)-7,12,16-trimethyl-17-oxooctadeca-1,3,5,7,9,11,13,15-octaen-1-ylidene)-3,5,5-trimethylcyclohexyl acetate
(2s,3r,4s,5r)-2-[2-(6-chlorododecyl)-5-(6-chlorotetradecyl)-3-hydroxyphenoxy]oxane-3,4,5-triol
C37H64Cl2O6 (674.4079704000001)
1-[5-({[3,4-dihydroxy-5-(2-hydroxy-1-methoxyethyl)oxolan-2-yl]oxy}methyl)-5-hydroxy-6-methylheptan-2-yl]-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthrene-3,3b,4,5,7-pentol
[(2r,3r,4s,5r,6r)-6-{[(1r,3as,3bs,7s,9ar,9bs,11ar)-9a,11a-dimethyl-1-[(2r)-pentan-2-yl]-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-3,4,5-tris(acetyloxy)oxan-2-yl]methyl acetate
(2s,3s)-2-{[(2r,3s)-1-hydroxy-2-{[(2s)-2-hydroxy-3-methylbutanoyl]oxy}-3-methylpentylidene]amino}-n-({[(2r)-1-[(2s)-2-(methoxycarbonyl)pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl](methyl)carbamoyl}methyl)-3-methylpentanimidic acid
C35H54N4O9 (674.3890594000001)
(2e,4s,5s,6e,8e)-10-[(2r,3s,6s,8s,9r)-9-butyl-8-[(1e,3e)-4-carboxy-3-methylbuta-1,3-dien-1-yl]-9-[(4-methoxy-4-oxobutanoyl)oxy]-3-methyl-1,7-dioxaspiro[5.5]undecan-2-yl]-5-hydroxy-4,8-dimethyldeca-2,6,8-trienoic acid
10-[9-butyl-8-(4-carboxy-3-methylbuta-1,3-dien-1-yl)-9-[(4-methoxy-4-oxobutanoyl)oxy]-3-methyl-1,7-dioxaspiro[5.5]undecan-2-yl]-5-hydroxy-4,8-dimethyldeca-2,6,8-trienoic acid
(1r,2r,3's,4'r,5s,5'r,6'r,10's,12's,16'r,18'r,21'r)-4-hydroxy-4',5,6',12',17',17'-hexamethyl-18'-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}-3,6,9'-trioxaspiro[bicyclo[3.1.0]hexane-2,8'-hexacyclo[11.9.0.0¹,²¹.0⁴,¹².0⁵,¹⁰.0¹⁶,²¹]docosan]-13'-en-3'-yl acetate
10-(2-{5-carboxy-1-[(3-carboxypropanoyl)oxy]-4-methylpenta-2,4-dien-1-yl}-8-methyl-2-pentyl-1,6-dioxaspiro[4.5]decan-7-yl)-5-hydroxy-4,8-dimethyldeca-2,6,8-trienoic acid
methyl 4,5-dihydroxy-6-{[2-hydroxy-4-(hydroxymethyl)-8a-(methoxycarbonyl)-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy}-5,6-dihydro-4h-pyran-2-carboxylate
(6r,14r)-13-hydroxy-2,2,4,4,8,8,10,10-octamethyl-12-(3-methylbutanoyl)-6,14-bis(2-methylpropyl)-6,14-dihydro-5,11-dioxapentaphene-1,3,7,9-tetrone
(2e,4r,5r,6e,8e)-10-[(2s,3r,6r,8r,9s)-8-[(1e,3e)-4-carboxy-3-methylbuta-1,3-dien-1-yl]-9-[(3-carboxypropanoyl)oxy]-3-methyl-9-pentyl-1,7-dioxaspiro[5.5]undecan-2-yl]-5-hydroxy-4,8-dimethyldeca-2,6,8-trienoic acid
(3r,4s,5e,8s,9r,10s)-9-hydroxy-10-[(2r,3s,4e,6e,9r,10s,11r,12e,14z)-10-hydroxy-3,15-dimethoxy-7,9,11,13-tetramethyl-16-oxo-1-oxacyclohexadeca-4,6,12,14-tetraen-2-yl]-2,4,8-trimethyl-7-oxoundec-5-en-3-yl butanoate
(4e,8e,12e)-4,6,8,10,12,14-hexamethyl-7,11-bis({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy})hexadeca-4,8,12-trien-3-one
(1s,2s,4r,6s,9s,10r,11r,14r,15r)-6-(2-methoxypropan-2-yl)-2,9,11,14,19,19-hexamethyl-17-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-oxapentacyclo[12.8.0.0²,¹¹.0⁴,¹⁰.0¹⁵,²⁰]docosa-16,20-diene-8,13,18-trione
methyl 14-{[4,5-dihydroxy-6-(hydroxymethyl)-3-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-4-hydroxy-2,6,10,14-tetramethylhexadeca-2,6,10,15-tetraenoate
4,6,8,10,12,14-hexamethyl-7,11-bis({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy})hexadeca-4,8,12-trien-3-one
5-{[(1r,3as,7r,8r,9as,11s,11ar)-7-(acetyloxy)-1-[(1s,5s)-7,7-dimethyl-6,8-dioxabicyclo[3.2.1]octan-4-yl]-11-hydroxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-8-yl]oxy}-3-hydroxy-3-methyl-5-oxopentanoic acid
3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl 2-(hydroxymethyl)-4a,6a,6b,11,12,14b-hexamethyl-2h,4h,4bh,5h,6h,7h,8h,9h,10h,12ah,14h,14ah,15h,16h,16ah-piceno[3,4-d][1,3]dioxine-8a-carboxylate
6-methyl-2-[4,7,10-tris(acetyloxy)-2-hydroxy-11a-(hydroxymethyl)-3a,6,6,9a-tetramethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]hept-5-en-3-yl acetate
methyl (1s,15r,17s,18s)-17-ethyl-6-[(1s,12r,14r,15z,18s)-15-ethylidene-18-(methoxycarbonyl)-17-methyl-10,17-diazatetracyclo[12.3.1.0³,¹¹.0⁴,⁹]octadeca-3(11),4,6,8-tetraen-12-yl]-3,13-diazapentacyclo[13.3.1.0²,¹⁰.0⁴,⁹.0¹³,¹⁸]nonadeca-2(10),4,6,8-tetraene-1-carboxylate
C42H50N4O4 (674.3831859999999)
(1s,3r,6r,8r,12s,13r,15r,16r,17r)-15-[(2r)-4-[(2r)-3,3-dimethyloxiran-2-yl]-4-oxobutan-2-yl]-13-hydroxy-7,7,12,16-tetramethyl-14-oxo-6-{[(2s,3r,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxy}pentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadec-10-en-17-yl acetate
2-({1-hydroxy-2-[(2-hydroxy-3-methylbutanoyl)oxy]-3-methylpentylidene}amino)-n-[({1-[2-(methoxycarbonyl)pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl}(methyl)carbamoyl)methyl]-3-methylpentanimidic acid
C35H54N4O9 (674.3890594000001)
4-{[5-(1,2-dimethoxyethyl)-3,4-dimethoxyoxolan-2-yl]oxy}-3,5-dimethoxy-2-(methoxymethyl)-6-[(1,2,4,5,6-pentamethoxyhexan-3-yl)oxy]oxane
5-{[7-(acetyloxy)-1-{7,7-dimethyl-6,8-dioxabicyclo[3.2.1]octan-4-yl}-11-hydroxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-8-yl]oxy}-3-hydroxy-3-methyl-5-oxopentanoic acid
1-[5-(2-isopropyl-3-methyloxiran-2-yl)-2-oxooxolan-3-yl]-9a,11a-dimethyl-7-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,3ah,5h,5ah,6h,7h,8h,9h,11h-cyclopenta[a]phenanthren-2-yl acetate
7-(acetyloxy)-15-[2,5-bis(acetyloxy)-6-(2-hydroxypropan-2-yl)oxan-3-yl]-2,6,6,10-tetramethylpentacyclo[12.3.1.0¹,¹⁴.0²,¹¹.0⁵,¹⁰]octadecan-3-yl acetate
15-[4-(3,3-dimethyloxiran-2-yl)-4-oxobutan-2-yl]-13-hydroxy-7,7,12,16-tetramethyl-14-oxo-6-[(3,4,5-trihydroxyoxan-2-yl)oxy]pentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadec-10-en-17-yl acetate
(1r,1'r,2r,3'r,4'r,5s,5'r,6'r,10's,12's,13's,16'r,18's,21'r)-4',5,6',12',17',17'-hexamethyl-4-oxo-18'-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}-3,6,9'-trioxaspiro[bicyclo[3.1.0]hexane-2,8'-hexacyclo[11.9.0.0¹,²¹.0⁴,¹².0⁵,¹⁰.0¹⁶,²¹]docosan]-3'-yl acetate
(1r,1's,2r,3'r,4s,4'r,5s,5'r,6'r,10's,12's,16'r,18's,21'r)-4-hydroxy-4',5,6',12',17',17'-hexamethyl-18'-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}-3,6,9'-trioxaspiro[bicyclo[3.1.0]hexane-2,8'-hexacyclo[11.9.0.0¹,²¹.0⁴,¹².0⁵,¹⁰.0¹⁶,²¹]docosan]-13'-en-3'-yl acetate
(2s,3r,4s,5r,6r)-3,4-dimethoxy-6-(methoxymethyl)-2-{[(2r,3r,4s,5s)-1,2,4,5,6-pentamethoxyhexan-3-yl]oxy}-5-{[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy}oxane
methyl (4s,5r,6r)-6-{[(2s,3r,4r,4ar,6ar,6bs,8as,12as,14ar,14br)-2-hydroxy-4-(hydroxymethyl)-8a-(methoxycarbonyl)-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy}-4,5-dihydroxy-5,6-dihydro-4h-pyran-2-carboxylate
3-({2,4-dihydroxy-6-[(3e,5e,14r,15s)-15-methyl-14-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}heptadeca-3,5-dien-1-yl]phenyl}methyl)-4-hydroxy-6-methylpyran-2-one
methyl (1s,15r,17r,18s)-17-ethyl-6-[(1s,12r,14r,15e,18r)-15-ethylidene-18-(methoxycarbonyl)-17-methyl-10,17-diazatetracyclo[12.3.1.0³,¹¹.0⁴,⁹]octadeca-3(11),4,6,8-tetraen-12-yl]-3,13-diazapentacyclo[13.3.1.0²,¹⁰.0⁴,⁹.0¹³,¹⁸]nonadeca-2(10),4,6,8-tetraene-1-carboxylate
C42H50N4O4 (674.3831859999999)
(1s,2r,3r,5r,7r,10s,11r,14r,15s)-7-(acetyloxy)-15-[(2s,3s,5r,6r)-2,5-bis(acetyloxy)-6-(2-hydroxypropan-2-yl)oxan-3-yl]-2,6,6,10-tetramethylpentacyclo[12.3.1.0¹,¹⁴.0²,¹¹.0⁵,¹⁰]octadecan-3-yl acetate
(2e,4r,5r,6e,8e)-10-[(2s,3r,6r,8r,9s)-8-[(1e,3e)-4-carboxy-3-methylbuta-1,3-dien-1-yl]-9-[(3-carboxypropanoyl)oxy]-3-methyl-9-(3-methylbutyl)-1,7-dioxaspiro[5.5]undecan-2-yl]-5-hydroxy-4,8-dimethyldeca-2,6,8-trienoic acid
(1r,3r,3as,3bs,4r,5r,5as,7s,9as,9br,11ar)-1-[(2r)-5-({[(2r,3r,4r,5r)-3,4-dihydroxy-5-[(1r)-2-hydroxy-1-methoxyethyl]oxolan-2-yl]oxy}methyl)-5-hydroxy-6-methylheptan-2-yl]-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthrene-3,3b,4,5,7-pentol
8-hydroxy-3,10,13,16-tetraisopropyl-2,7,12-trimethyl-6-(pent-4-yn-1-yl)-3h,6h,7h,10h,13h,16h,19h,20h,21h,21ah-pyrrolo[2,1-f]1,10-dioxa-4,7,13,16-tetraazacyclononadecane-1,4,11,14,17-pentone
(3s)-5-{[(1r,3as,5ar,7r,8r,9as,11s,11ar)-7-(acetyloxy)-1-[(1r,4r,5r)-7,7-dimethyl-6,8-dioxabicyclo[3.2.1]octan-4-yl]-11-hydroxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,4h,5h,5ah,7h,8h,9h,10h,11h-cyclopenta[a]phenanthren-8-yl]oxy}-3-hydroxy-3-methyl-5-oxopentanoic acid
15-benzyl-8,11,17-trihydroxy-6-(hydroxymethyl)-3,9-diisopropyl-13-methyl-12,18-bis(2-methylpropyl)-1,4-dioxa-7,10,13,16-tetraazacyclooctadeca-7,10,16-triene-2,5,14-trione
C35H54N4O9 (674.3890594000001)